Bio-Techne Welcomes Dr. Amy E. Herr to its Board of Directors
On February 1, 2025, Bio-Techne Corporation (NASDAQ: TECH) reinforced its leadership by appointing Dr. Amy E. Herr, Ph.D., to its Board of Directors. Dr. Herr, an esteemed Chancellor's Professor of Bioengineering at the University of California, Berkeley, is expected to contribute significantly to the company, particularly as a member of the Science and Technology Committee. Her extensive experience aligns perfectly with Bio-Techne's strategic vision.
Dr. Herr is no stranger to the world of scientific innovation. She also serves as the Vice President of the Chan Zuckerberg Biohub Network, an initiative aimed at advancing tools and understanding within the life sciences to combat human diseases. Since joining UC Berkeley in 2007, she has held various prominent roles, including the Founding Executive Director of the Bakar BioEnginuity Hub, which supports the commercialization of academic research.
In addition to her academic roles, Dr. Herr’s past experience includes being a co-founder of Zephyrus Biosciences, an enterprise acquired by Bio-Techne in 2016. With a Doctorate in Mechanical Engineering from Stanford University and a Bachelor’s degree in Applied Science from Caltech, Dr. Herr’s academic credentials provide her with a solid foundation in both engineering and life sciences.
Her appointment fulfills a vital part of Bio-Techne's succession planning. It comes as the company prepares for the retirement of directors Randy Steer and Dr. Roeland Nusse. Dr. Herr will replace Dr. Nusse, who is set to retire later in 2025, ensuring that the board continues to thrive with fresh insights and groundbreaking experience.
Kim Kelderman, President and CEO of Bio-Techne, voiced the company's enthusiasm for Dr. Herr’s appointment, stating, “Dr. Herr’s profound biological and engineering expertise is a perfect match for our board and the company’s strategic direction.” This sentiment was echoed by Bob Baumgartner, the Board Chairman, who highlighted her scientific credentials and the value she will bring to Bio-Techne’s ongoing growth, particularly in the proteomic analytical instrument sector.
Bio-Techne, a global leader in life sciences, is committed to delivering innovative tools and bioactive reagents that advance both research and clinical diagnostics. In fiscal 2024, the company reported approximately $1.2 billion in net sales and boasts a workforce of around 3,100 employees worldwide. By incorporating leaders like Dr. Herr, Bio-Techne aims to maintain its commitment to scientific excellence and advance research processes that lead to a deeper understanding of biological challenges and disease progression.
For those keen on following Bio-Techne’s journey or learning more about its extensive portfolio of products and services, they can visit the company’s website or engage on its social media platforms, including Facebook, LinkedIn, Twitter, and YouTube. This new phase for Bio-Techne not only signifies a strong commitment to innovation but also a strategic move to ensure the board is equipped with exceptional talent in tackling future challenges in the life sciences arena.
Dr. Herr is no stranger to the world of scientific innovation. She also serves as the Vice President of the Chan Zuckerberg Biohub Network, an initiative aimed at advancing tools and understanding within the life sciences to combat human diseases. Since joining UC Berkeley in 2007, she has held various prominent roles, including the Founding Executive Director of the Bakar BioEnginuity Hub, which supports the commercialization of academic research.
In addition to her academic roles, Dr. Herr’s past experience includes being a co-founder of Zephyrus Biosciences, an enterprise acquired by Bio-Techne in 2016. With a Doctorate in Mechanical Engineering from Stanford University and a Bachelor’s degree in Applied Science from Caltech, Dr. Herr’s academic credentials provide her with a solid foundation in both engineering and life sciences.
Her appointment fulfills a vital part of Bio-Techne's succession planning. It comes as the company prepares for the retirement of directors Randy Steer and Dr. Roeland Nusse. Dr. Herr will replace Dr. Nusse, who is set to retire later in 2025, ensuring that the board continues to thrive with fresh insights and groundbreaking experience.
Kim Kelderman, President and CEO of Bio-Techne, voiced the company's enthusiasm for Dr. Herr’s appointment, stating, “Dr. Herr’s profound biological and engineering expertise is a perfect match for our board and the company’s strategic direction.” This sentiment was echoed by Bob Baumgartner, the Board Chairman, who highlighted her scientific credentials and the value she will bring to Bio-Techne’s ongoing growth, particularly in the proteomic analytical instrument sector.
Bio-Techne, a global leader in life sciences, is committed to delivering innovative tools and bioactive reagents that advance both research and clinical diagnostics. In fiscal 2024, the company reported approximately $1.2 billion in net sales and boasts a workforce of around 3,100 employees worldwide. By incorporating leaders like Dr. Herr, Bio-Techne aims to maintain its commitment to scientific excellence and advance research processes that lead to a deeper understanding of biological challenges and disease progression.
For those keen on following Bio-Techne’s journey or learning more about its extensive portfolio of products and services, they can visit the company’s website or engage on its social media platforms, including Facebook, LinkedIn, Twitter, and YouTube. This new phase for Bio-Techne not only signifies a strong commitment to innovation but also a strategic move to ensure the board is equipped with exceptional talent in tackling future challenges in the life sciences arena.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.